Symbols / FEED Stock $1.24 +1.64% ENvue Medical, Inc.

Healthcare • Medical Devices • United States • NCM
FEED (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. Doron Robert Besser M.D.
Exch · Country NCM · United States
Market Cap 4.59M
Enterprise Value -1.66M
Income -16.77M
Sales 2.55M
FCF (ttm) -4.14M
Book/sh 30.44
Cash/sh 3.84
Employees 12
Insider 10d
IPO May 28, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E
PEG
P/S 1.80
P/B 0.04
P/C
EV/EBITDA 0.15
EV/Sales -0.65
Quick Ratio 0.72
Current Ratio 1.09
Debt/Eq 3.57
LT Debt/Eq
EPS (ttm) -26.69
EPS next Y
EPS Growth
Revenue Growth -29.70%
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next) 2019-11-19
Earnings (prior) 2019-11-19
ROA -32.78%
ROE -106.58%
ROIC
Gross Margin 5.99%
Oper. Margin -11.73%
Profit Margin 0.00%
Shs Outstand 3.70M
Shs Float 860.38K
Insider Own 8.91%
Instit Own 0.61%
Short Float 0.30%
Short Ratio 0.04
Short Interest 10.98K
52W High 42.10
vs 52W High -97.05%
52W Low 0.99
vs 52W Low 25.25%
Beta 1.59
Impl. Vol.
Rel Volume 1.95
Avg Volume 2.97M
Volume 5.80M
Target (mean)
Tgt Median
Tgt Low
Tgt High
# Analysts
Recom None
Prev Close $1.22
Price $1.24
Change 1.64%
About

ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Arlington Heights, Illinois.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.24
Low
High
Mean
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-02 BANK OF AMERICA CORPORATION Beneficial Owner of more than 10% of a Class of Security 2,918 $2.42 $7,062
2026-01-14 GLIBERT CHRISTIAN MICHAEL Beneficial Owner of more than 10% of a Class of Security 240,000 $1.70 $408,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.55
-0.20%
2.56
+12.05%
2.28
+203.59%
0.75
Operating Revenue
2.55
-0.20%
2.56
+12.05%
2.28
+203.59%
0.75
Cost Of Revenue
2.40
+128.57%
1.05
+40.75%
0.75
+27.52%
0.58
Reconciled Cost Of Revenue
2.40
+128.57%
1.05
+40.75%
0.75
+27.52%
0.58
Gross Profit
0.15
-89.85%
1.51
-1.89%
1.54
+820.36%
0.17
Operating Expense
11.89
+133.56%
5.09
+2.35%
4.97
-3.98%
5.18
Research And Development
1.76
+93.84%
0.91
+391.35%
0.18
-34.63%
0.28
Selling General And Administration
10.13
+142.19%
4.18
-12.68%
4.79
-2.21%
4.90
Selling And Marketing Expense
2.49
+246.25%
0.72
-16.67%
0.86
-10.47%
0.96
General And Administrative Expense
7.63
+120.54%
3.46
-11.80%
3.92
-0.18%
3.93
Other Gand A
7.63
+120.54%
3.46
-11.80%
3.92
-0.18%
3.93
Total Expenses
14.29
+132.70%
6.14
+7.36%
5.72
-0.78%
5.76
Operating Income
-11.73
-227.61%
-3.58
-4.25%
-3.44
+31.44%
-5.01
Total Operating Income As Reported
-22.89
-539.00%
-3.58
-4.25%
-3.44
+31.44%
-5.01
EBITDA
-10.84
-202.65%
-3.58
-0.99%
-3.55
+29.99%
-5.07
Normalized EBITDA
0.32
+108.82%
-3.58
-0.99%
-3.55
+29.99%
-5.07
Reconciled Depreciation
0.90
+89600.00%
0.00
+0.00%
0.00
+0.00%
0.00
EBIT
-11.73
-227.61%
-3.58
-0.99%
-3.55
+29.98%
-5.07
Total Unusual Items
-11.15
0.00
0.00
Total Unusual Items Excluding Goodwill
-11.15
0.00
0.00
Special Income Charges
-11.15
0.00
0.00
Other Special Charges
Impairment Of Capital Assets
11.15
0.00
Net Income
-18.18
-390.82%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Pretax Income
-18.49
-401.68%
-3.69
-0.11%
-3.68
+31.98%
-5.41
Net Non Operating Interest Income Expense
4.40
+4327.88%
-0.10
+57.72%
-0.25
+38.65%
-0.40
Interest Expense Non Operating
0.14
+0.00%
0.14
-61.10%
0.35
Net Interest Income
4.40
+4327.88%
-0.10
+57.72%
-0.25
+38.65%
-0.40
Interest Expense
0.14
+0.00%
0.14
-61.10%
0.35
Other Income Expense
-11.15
Other Non Operating Income Expenses
Gain On Sale Of Security
Tax Provision
-0.31
-1715.79%
0.02
-34.48%
0.03
-17.14%
0.04
Tax Rate For Calcs
0.00
-92.10%
0.00
+34900.00%
0.00
-99.71%
0.00
Tax Effect Of Unusual Items
-0.19
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-18.18
-390.82%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Net Income From Continuing Operation Net Minority Interest
-18.18
-390.82%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Net Income From Continuing And Discontinued Operation
-18.18
-390.82%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Net Income Continuous Operations
-18.18
-390.82%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Normalized Income
-7.22
-94.77%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Net Income Common Stockholders
-16.77
-352.77%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Otherunder Preferred Stock Dividend
-3.51
0.00
Diluted EPS
-26.69
+80.56%
-137.30
+41.12%
-233.20
+44.79%
-422.40
Basic EPS
-26.69
+80.56%
-137.30
+41.12%
-233.20
+44.79%
-422.40
Basic Average Shares
0.63
+2229.20%
0.03
+69.61%
0.02
+23.28%
0.01
Diluted Average Shares
0.63
+2229.20%
0.03
+69.61%
0.02
+23.28%
0.01
Diluted NI Availto Com Stockholders
-16.77
-352.77%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Preferred Stock Dividends
2.10
Total Other Finance Cost
-4.40
-4327.88%
0.10
-6.31%
0.11
+105.56%
0.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
41.12
+1033.20%
3.63
-45.62%
6.67
+13.52%
5.88
Current Assets
7.27
+118.28%
3.33
-48.65%
6.49
+15.65%
5.61
Cash Cash Equivalents And Short Term Investments
4.22
+461.70%
0.75
-77.09%
3.28
+21.01%
2.71
Cash And Cash Equivalents
4.22
+461.70%
0.75
-77.09%
3.28
+21.01%
2.71
Cash Financial
4.22
+461.70%
0.75
-77.09%
3.28
+21.01%
2.71
Receivables
0.54
+102.61%
0.27
-36.94%
0.42
+289.91%
0.11
Accounts Receivable
0.29
+194.90%
0.10
-69.18%
0.32
+3433.33%
0.01
Other Receivables
0.25
+49.41%
0.17
+58.88%
0.11
+7.00%
0.10
Inventory
2.34
+6.66%
2.19
-19.80%
2.73
+25.61%
2.17
Raw Materials
1.80
+23.19%
1.46
+596.19%
0.21
+600.00%
0.03
Finished Goods
0.54
-26.47%
0.73
-71.09%
2.52
+17.58%
2.15
Prepaid Assets
0.14
+14.17%
0.12
+155.32%
0.05
-92.32%
0.61
Restricted Cash
0.03
0.00
Total Non Current Assets
33.85
+11260.07%
0.30
+59.36%
0.19
-30.74%
0.27
Net PPE
0.25
+96.80%
0.12
+941.67%
0.01
-86.36%
0.09
Gross PPE
0.25
+96.80%
0.12
+941.67%
0.01
-86.36%
0.09
Other Properties
0.25
+96.80%
0.12
+941.67%
0.01
-86.36%
0.09
Goodwill And Other Intangible Assets
33.46
0.00
Goodwill
29.08
0.00
Other Intangible Assets
4.38
Non Current Accounts Receivable
0.02
Other Non Current Assets
0.00
-66.67%
0.00
Total Liabilities Net Minority Interest
7.63
+154.06%
3.00
+11.76%
2.69
+1.51%
2.65
Current Liabilities
6.66
+144.67%
2.72
+10.92%
2.45
+5.96%
2.32
Payables And Accrued Expenses
3.06
+469.52%
0.54
-77.61%
2.40
+8.54%
2.21
Payables
1.09
+2210.64%
0.05
-98.04%
2.40
+8.54%
2.21
Accounts Payable
0.72
+1429.79%
0.05
-65.94%
0.14
+109.09%
0.07
Other Payable
0.25
-90.41%
2.61
+15.14%
2.27
+5.45%
2.15
Current Accrued Expenses
1.98
+302.85%
0.49
Employee Benefits
0.13
-38.89%
0.22
-0.46%
0.22
-2.69%
0.22
Total Tax Payable
0.12
0.00
Current Debt And Capital Lease Obligation
1.17
+2148.08%
0.05
+940.00%
0.01
-93.83%
0.08
Current Debt
1.08
Current Capital Lease Obligation
0.09
+71.15%
0.05
+940.00%
0.01
-93.83%
0.08
Current Deferred Liabilities
0.17
+1066.67%
0.01
-67.39%
0.05
+119.05%
0.02
Current Deferred Revenue
0.17
+1066.67%
0.01
-67.39%
0.05
+119.05%
0.02
Other Current Liabilities
2.25
+6.38%
2.12
Total Non Current Liabilities Net Minority Interest
0.97
+245.36%
0.28
+20.69%
0.23
-29.70%
0.33
Long Term Debt And Capital Lease Obligation
0.03
-56.25%
0.06
0.00
Long Term Capital Lease Obligation
0.03
-56.25%
0.06
0.00
Defined Pension Benefit
0.12
-27.75%
0.17
-0.57%
0.17
-2.79%
0.18
Non Current Pension And Other Postretirement Benefit Plans
0.13
-38.89%
0.22
-0.46%
0.22
-2.69%
0.22
Non Current Deferred Liabilities
0.00
-100.00%
0.01
-85.98%
0.11
Non Current Deferred Revenue
0.00
-100.00%
0.01
-85.98%
0.11
Stockholders Equity
33.50
+5242.42%
0.63
-84.28%
3.99
+23.35%
3.23
Common Stock Equity
33.50
+5242.42%
0.63
-84.28%
3.99
+23.35%
3.23
Capital Stock
0.00
+0.00%
0.00
-50.00%
0.00
+0.00%
0.00
Common Stock
0.00
+0.00%
0.00
-50.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
1.10
+190.39%
0.38
+1937.09%
0.02
+24.69%
0.01
Ordinary Shares Number
1.10
+2803.92%
0.04
+103.71%
0.02
+24.69%
0.01
Additional Paid In Capital
124.06
+75.95%
70.51
+0.51%
70.15
+6.88%
65.63
Retained Earnings
-90.48
-29.63%
-69.80
-5.61%
-66.10
-5.95%
-62.38
Gains Losses Not Affecting Retained Earnings
-0.08
+0.00%
-0.08
-19.40%
-0.07
-272.22%
-0.02
Other Equity Adjustments
-0.08
+0.00%
-0.08
-19.40%
-0.07
-272.22%
-0.02
Total Equity Gross Minority Interest
33.50
+5242.42%
0.63
-84.28%
3.99
+23.35%
3.23
Total Capitalization
33.50
+5242.42%
0.63
-84.28%
3.99
+23.35%
3.23
Working Capital
0.61
+0.33%
0.61
-84.90%
4.03
+22.47%
3.29
Invested Capital
34.58
+5414.67%
0.63
-84.28%
3.99
+23.35%
3.23
Total Debt
1.20
+931.90%
0.12
+2220.00%
0.01
-93.83%
0.08
Capital Lease Obligations
0.12
+0.86%
0.12
+2220.00%
0.01
-93.83%
0.08
Net Tangible Assets
0.04
-94.42%
0.63
-84.28%
3.99
+23.35%
3.23
Tangible Book Value
0.04
-94.42%
0.63
-84.28%
3.99
+23.35%
3.23
Current Notes Payable
1.08
0.00
Derivative Product Liabilities
0.81
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-9.37
-272.50%
-2.52
+30.15%
-3.60
+48.80%
-7.04
Cash Flow From Continuing Operating Activities
-9.37
-272.38%
-2.52
+30.15%
-3.60
+48.80%
-7.04
Net Income From Continuing Operations
-18.18
-390.82%
-3.71
+0.16%
-3.71
+31.88%
-5.45
Depreciation Amortization Depletion
0.90
+89600.00%
0.00
+0.00%
0.00
+0.00%
0.00
Depreciation And Amortization
0.90
+89600.00%
0.00
+0.00%
0.00
+0.00%
0.00
Other Non Cash Items
1.68
+1558.42%
0.10
-25.19%
0.14
-61.10%
0.35
Stock Based Compensation
0.00
-100.00%
0.36
+21.50%
0.29
-17.23%
0.35
Asset Impairment Charge
11.15
0.00
Deferred Tax
-0.37
0.00
Deferred Income Tax
-0.37
0.00
Operating Gains Losses
-6.20
Gain Loss On Investment Securities
-6.20
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
0.00
-87.50%
0.02
Change In Working Capital
1.66
+127.63%
0.73
+327.02%
-0.32
+86.03%
-2.31
Change In Receivables
-0.28
-423.53%
0.09
-65.86%
0.25
+185.57%
-0.29
Changes In Account Receivables
-0.18
-181.00%
0.22
+171.52%
-0.31
-261.78%
0.19
Change In Inventory
0.25
-53.97%
0.54
+197.13%
-0.56
+72.15%
-2.00
Change In Payables And Accrued Expense
1.54
+920.53%
0.15
+184.91%
0.05
-3.64%
0.06
Change In Accrued Expense
-0.04
0.00
+100.00%
-0.00
+50.00%
-0.00
Change In Payable
1.58
+944.37%
0.15
+179.63%
0.05
-5.26%
0.06
Change In Account Payable
0.55
+706.59%
-0.09
-226.39%
0.07
+442.86%
-0.02
Change In Other Working Capital
0.16
+447.83%
-0.05
+31.34%
-0.07
+2.90%
-0.07
Change In Other Current Assets
0.07
+117.65%
0.03
Change In Other Current Liabilities
-0.09
-150.00%
-0.03
Investing Cash Flow
0.09
+3033.33%
-0.00
-200.00%
-0.00
+66.67%
-0.00
Cash Flow From Continuing Investing Activities
0.09
+3033.33%
-0.00
-200.00%
-0.00
+66.67%
-0.00
Net PPE Purchase And Sale
-0.06
-1900.00%
-0.00
-200.00%
-0.00
+66.67%
-0.00
Purchase Of PPE
-0.06
-1900.00%
-0.00
-200.00%
-0.00
+66.67%
-0.00
Capital Expenditure
-0.06
-1900.00%
-0.00
-200.00%
-0.00
+66.67%
-0.00
Net Business Purchase And Sale
0.15
0.00
Financing Cash Flow
12.79
+1278500.00%
0.00
-99.98%
4.22
+101.82%
2.09
Cash Flow From Continuing Financing Activities
12.79
+1278500.00%
0.00
-99.98%
4.22
+101.82%
2.09
Net Issuance Payments Of Debt
-1.42
0.00
Issuance Of Debt
1.66
0.00
Repayment Of Debt
-3.08
0.00
Long Term Debt Issuance
Long Term Debt Payments
-1.30
0.00
Net Long Term Debt Issuance
-1.30
0.00
Short Term Debt Issuance
1.66
0.00
Short Term Debt Payments
-1.78
0.00
Net Short Term Debt Issuance
-0.12
0.00
Net Common Stock Issuance
19.09
0.00
-100.00%
4.21
+101.67%
2.09
Repurchase Of Capital Stock
-5.00
0.00
Proceeds From Stock Option Exercised
0.10
+10100.00%
0.00
-85.71%
0.01
+250.00%
0.00
Net Other Financing Charges
0.01
Changes In Cash
3.50
+239.08%
-2.52
-506.79%
0.62
+112.52%
-4.95
Effect Of Exchange Rate Changes
0.00
+100.00%
-0.01
+73.47%
-0.05
+37.18%
-0.08
Beginning Cash Position
0.75
-77.09%
3.28
+21.01%
2.71
-64.93%
7.74
End Cash Position
4.25
+465.69%
0.75
-77.09%
3.28
+21.01%
2.71
Free Cash Flow
-9.43
-274.43%
-2.52
+30.09%
-3.60
+48.81%
-7.04
Interest Paid Supplemental Data
0.03
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.05
0.00
0.00
0.00
Common Stock Issuance
19.09
0.00
-100.00%
4.21
+101.67%
2.09
Issuance Of Capital Stock
19.09
0.00
-100.00%
4.21
+101.67%
2.09
Net Preferred Stock Issuance
-5.00
0.00
Preferred Stock Payments
-5.00
0.00
Sale Of Business
0.15
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category